The Travel Time Information System (TTIS) is an Intelligent Traffic Control System installed in Poland. As is common, travel time is the only factor in the decision about rerouting traffic, while a route recommendation may consider multiple criteria, including road safety. The aim of the paper is to analyze the safety level of the entire road network when traffic is rerouted on paths with different road categories, intersection types, road environments, and densities of access points. Furthermore, a comparison between traffic operation and road safety performance was carried out, considering travel time and delay, and we predicted the number of crashes for each possible route. The results of the present study allow for maximizing safety or traffic operation characteristics, providing an effective tool in the management of the rural road system. The paper provides a methodology that can be transferred to other TTISs for real-time management of the road network.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435770 | PMC |
| http://dx.doi.org/10.3390/s20154145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of clinically relevant variants in the gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Hemasphere
January 2025
Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic.
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.
View Article and Find Full Text PDFInitial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Front Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDF"If that would have lessened my symptoms, that would have been great...": a qualitative study about the acceptability of tecovirimat as treatment for mpox.
BMC Med
January 2025
Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.
View Article and Find Full Text PDFTrends in alcohol, MDMA, methylamphetamine and THC in injured and deceased motor vehicle drivers and motorcyclists over a decade (2010-2019) in Victoria, Australia.
Inj Prev
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: Driving under the influence of alcohol and other drugs contributes significantly to road traffic crashes worldwide. This study explored trends of alcohol, methylamphetamine (MA), 3,4-methylenedioxy-N-methylamphetamine (MDMA) and Δ9-tetrahydrocannabinol (THC), in road crashes from 2010 to 2019 in Victoria, Australia.
Methods: We conducted a cross-sectional analysis using data from the Victorian Institute of Forensic Medicine and Victoria Police, examining proscribed drug detections in road crashes.
Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).
Thromb Haemost
January 2025
Centre de Ressources et Compétences des Maladies Hémorragiques Constitutionnelles, CHU Clermont-Ferrand, Estaing Hospital, Clermont-Ferrand, France.
Background: The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed to validate the psychometric properties of Hemo-FAST for assessment of joint health in people with haemophilia (PwH).
Methods: PwH A or B aged ≥18 years completed questionnaires including the PRO part of Hemo-FAST and the short-form 36 health survey (SF-36) during one study visit.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!